跳至主要内容
临床试验/NCT02663375
NCT02663375已完成不适用

Symetis ACURATE TA™ Valve Implantation Using TransApical Access:SAVI2 Registry

Symetis SA27 个研究点 分布在 4 个国家目标入组 250 人开始时间: 2013年11月最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
250
试验地点
27
主要终点
Rate of all-cause mortality at 30 days follow-up

研究概览

简要总结

Post-market registry on ACURATE TA™ Transapical Aortic Bioprosthesis and ACURATE TA™ Delivery System implantation in patients presenting severe symptomatic aortic stenosis to collect continued surveillance data pertaining to safety and performance of the device.

详细描述

The SAVI2 registry is a single arm, prospective, multicenter, non-randomized and open registry up to 1 year follow-up with the Symetis ACURATE TA™.

The ACURATE TA™ is an aortic bioprosthesis for minimal invasive implantation via transapical access to treat patients with severe symptomatic aortic stenosis where conventional aortic valve replacement (AVR) via open surgery is considered to be associated with high surgical risk.

The primary objectives of the registry is to further evaluate the safety and performance of the implantation and the safety at 30-Day Follow-up.

研究设计

研究类型
Observational
观察模型
Case Only
时间视角
Prospective

入排标准

性别
All
接受健康志愿者

入选标准

  • Patient has severe aortic stenosis
  • Native aortic annulus diameter from ≥ 21mm up to ≤ 27mm
  • Patient willing to participate in the study and provides signed EC-approved informed consent
  • The subject and treating physician agree the subject will return for all required post-procedure follow-up visits

排除标准

  • Patients are excluded from the registry if they are not eligible for transcatheter treatment of severe aortic stenosis with the ACURATE TA™ and Delivery System as per the Instructions For Use.

结局指标

主要结局

Rate of all-cause mortality at 30 days follow-up

时间窗: 30-Day Follow-up

Rate of all-cause mortality at 30 days follow-up

次要结局

  • Device success at 7 Day or Discharge (which ever comes first) and at 12 months follow-up(7-Days Follow-up and 12-Months Follow-up)
  • Rate of clinical endpoints (VARC II) at 30 days and 12 months(30-Days and 12 Months Follow-up)
  • Functional improvement from baseline as per NYHA Functional Classification at 30 days and 12 months(30-Day and 12-Month Follow-up)
  • Procedural success post-implant(Procedure to 24h Post-implantation)

研究者

发起方
Symetis SA
申办方类型
Industry
责任方
Sponsor

研究点 (27)

Loading locations...

相似试验